Amsterdam, E. A. et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130, 23542394 (2014).

Google Scholar

Kernan, W. N. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45, 21602236 (2014).

Google Scholar

Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33, 25692619 (2012).

Google Scholar

Parodi, G. et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306, 12151223 (2011).

CAS Google Scholar

Papathanasiou, A., Goudevenos, J. & Tselepis, A. D. Resistance to aspirin and clopidogrel: Possible mechanisms, laboratory investigation, and clinical significance. Hellenic J. Cardiol. 48, 352363 (2007).

Google Scholar

Mallouk, N. et al. Prevalence of poor biological response to clopidogrel: A systematic review. Thromb. Haemost. 107, 494506 (2012).

CAS Google Scholar

Wei, Y.-Q., Wang, D.-G., Yang, H. & Cao, H. Cytochrome P450 CYP 2C19*2 associated with adverse 1-year cardiovascular events in patients with acute coronary syndrome. PLoS ONE 10, e0132561 (2015).

Google Scholar

Jia, D. et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke 44, 17171719 (2013).

CAS Google Scholar

Berger, J. S. et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 120, 2337 (2009).

CAS Google Scholar

Silvain, J. et al. High on-thienopyridine platelet reactivity in elderly coronary patients: The SENIOR-PLATELET study. Eur. Heart J. 33, 12411249 (2012).

CAS Google Scholar

Labarthe, B., Throux, P., Angio, M. & Ghitescu, M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J. Am. Coll. Cardiol. 46, 638645 (2005).

CAS Google Scholar

Sangkuhl, K., Klein, T. E. & Altman, R. B. Clopidogrel pathway. Pharmacogenet. Genomics 20, 463465 (2010).

CAS Google Scholar

Hulot, J.-S. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 22442247 (2006).

CAS Google Scholar

Brandt, J. T. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 24292436 (2007).

CAS Google Scholar

Giusti, B. et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics 17, 10571064 (2007).

CAS Google Scholar

Trenk, D. et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol. 51, 19251934 (2008).

CAS Google Scholar

Fontana, P., Senouf, D. & Mach, F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb. Res. 121, 463468 (2008).

CAS Google Scholar

Gaedigk, A. et al. The pharmacogene variation (PharmVar) consortium: Incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin. Pharmacol. Ther. 103, 399401 (2018).

CAS Google Scholar

Sibbing, D. et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur. Heart J. 30, 916922 (2009).

CAS Google Scholar

de Morais, S. M. et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 1541915422 (1994).

Google Scholar

Botton, M. R. et al. PharmVar GeneFocus: CYP2C19. Clin. Pharmacol. Ther. 109, 352366 (2021).

Google Scholar

Ferreiro, J. L. & Angiolillo, D. J. Clopidogrel response variability: Current status and future directions. Thromb. Haemost. 102, 714 (2009).

CAS Google Scholar

Chan, M. Y. Clopidogrel pharmacogenetics of east, south and other Asian populations. Eur. Heart J. Suppl. 14, A41A42 (2012).

CAS Google Scholar

Abid, L. et al. Impact of cytochrome P450 2C19*2 polymorphism on the clinical cardiovascular events after stent implantation in patients receiving clopidogrel of a southern Tunisian region. World J. Cardiovasc. Dis. 3, 410 (2013).

Google Scholar

Mller, I. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 89, 783787 (2003).

Google Scholar

Angiolillo, D. J. et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb. Res. 115, 101108 (2005).

CAS Google Scholar

Varenhorst, C. et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur. Heart J. 30, 17441752 (2009).

CAS Google Scholar

Mrginean, A., Bnescu, C., Scridon, A. & Dobreanu, M. Anti-platelet therapy resistanceConcept, mechanisms and platelet function tests in intensive care facilities. J. Crit. Care Med. 2, 615 (2016).

Google Scholar

Mega, J. L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354362 (2009).

CAS Google Scholar

Rath, P. C. et al. A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI. Indian Heart J. 67, 114121 (2015).

CAS Google Scholar

Bhatt, D. L. et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The CHARISMA genetics study. Eur. Heart J. 33, 21432150 (2012).

CAS Google Scholar

Kim, K. A., Park, P. W., Hong, S. J. & Park, J.-Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 84, 236242 (2008).

CAS Google Scholar

Osmancik, P., Paulu, P., Tousek, P., Kocka, V. & Widimsky, P. High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. J. Thromb. Thrombolysis 33, 349354 (2012).

CAS Google Scholar

Mannini, L. et al. Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients. Clin. Hemorheol. Microcirc. 35, 175181 (2006).

CAS Google Scholar

Li, L. et al. Clopidogrel resistance of patients with coronary artery disease and its correlation with platelet count and mean platelet volume. Zhonghua Yi Xue Za Zhi 93, 916920 (2013).

CAS Google Scholar

Uzun, F. et al. Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postepy Kardiol Interwencyjnej 11, 1925 (2015).

Google Scholar

Angiolillo, D. J. & Suryadevara, S. Aspirin and clopidogrel: Efficacy and resistance in diabetes mellitus. Best Pract. Res. Clin. Endocrinol. Metab. 23, 375388 (2009).

CAS Google Scholar

Ertugrul, D. T. et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 95, 28972901 (2010).

CAS Google Scholar

Cecchi, E. et al. Effect of blood hematocrit and erythrocyte deformability on adenosine 5-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy. Am. J. Cardiol. 104, 764768 (2009).

CAS Google Scholar

Zaccardi, F., Pitocco, D., Willeit, P. & Laukkanen, J. A. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: Systematic review and meta-analyses of randomized clinical trials. Atherosclerosis 240, 439445 (2015).

CAS Google Scholar

Ibrahim, O. et al. Evaluation of aspirin and clopidogrel resistance in patients with acute coronary syndrome by using adenosine diposphate test and aspirin test. Pak. J. Med. Sci. 29, 97102 (2013).

Google Scholar

Ojeifo, O. et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: Insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc. Interv. 6, 12751281 (2013).

Google Scholar

Mitsios, J. V. et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 109, 13351338 (2004).

CAS Google Scholar

Lau, W. C. et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 107, 3237 (2003).

CAS Google Scholar

Brophy, J. M., Babapulle, M. N., Costa, V. & Rinfret, S. A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. Am. Heart J. 152, 263269 (2006).

CAS Google Scholar

Verdoia, M. et al. Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy. Atherosclerosis 243, 389394 (2015).

CAS Google Scholar

Gonzlez, A. et al. Effect of CYP2C19 polymorphisms on the platelet response to clopidogrel and influence on the effect of high versus standard dose clopidogrel in carotid artery stenting. Eur. J. Vasc. Endovasc. Surg. 51, 175186 (2016).

Google Scholar

Cunningham, F. et al. Ensembl 2019. Nucleic Acids Res. 47, 745751 (2019).

Google Scholar

Rozas, J. et al. DnaSP 6: DNA sequence polymorphism analysis of large data sets. Mol. Biol. Evol. 34, 32993302 (2017).

CAS Google Scholar

Excoffier, L., Laval, G. & Schneider, S. Arlequin (version 3.0): An integrated software package for population genetics data analysis. Evol. Bioinform. Online 1, 4750 (2007).

Google Scholar

Originally posted here:
Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients | Scientific Reports - Nature.com

Comments are closed.